Loading clinical trials...
Loading clinical trials...
A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages
Conditions
Interventions
MF59
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Locations
10
United States
Emory Vaccine Center - The Hope Clinic
Decatur, Georgia, United States
University of Iowa - Vaccine Research and Education Unit
Iowa City, Iowa, United States
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
Baltimore, Maryland, United States
Saint Louis University - Center for Vaccine Development
St Louis, Missouri, United States
Duke Human Vaccine Institute - Duke Clinical Vaccine Unit
Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center - Infectious Diseases
Cincinnati, Ohio, United States
Start Date
October 1, 2014
Primary Completion Date
July 1, 2016
Completion Date
July 1, 2016
Last Updated
July 6, 2017
NCT07240558
NCT02839330
NCT03682120
NCT03318315
NCT00561184
NCT00895544
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions